logo
  

Ryanair April Passengers Up 8% YoY

Ryanair Holdings plc (RYA.L,RYAAY) reported guests of 17.3 million for the month of April, 2024, compared to 16.0 million, a year ago, an increase of 8%. Load factor was 92% compared to 94%, prior year, down 2 percentage points. The airline operated over 98,400 flights in April. Almost 700 flights were cancelled due to Israel/Gaza conflict and over 340 flights cancelled due to the French ATC strike.

For the rolling period, guests were 185.0 million, an increase of 9% from prior year. Load factor was 93%, a decline of 1 percentage point.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast. Shares of Marks and Spencer Group Plc or M&S were gaining more than 7 percent in the morning trading in London after the retail major reported Wednesday significantly higher profit and sales in its fiscal 2024. The company also announced a dividend, and said it is confident to make further progress in 2025 and beyond.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT